Skip to content
Research/Peptides/Bremelanotide (PT-141)

Bremelanotide (PT-141)

compound

preliminary evidencePublic

PT-141, Vyleesi. Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.

Category: Peptides·Updated 5/19/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

Bremelanotide (PT-141)

PT-141, Vyleesi. Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon